Rtw Investments Reduces $53M in Natera, Inc. ($NTRA)

RTW Investments has cut its stake in Natera, Inc. (NasdaqGS: NTRA) by 250,000 shares, according to its latest Form 13F filing with the SEC. This reduction represents a 16.67% decrease in its holdings, leaving RTW with 1.25 million shares valued at approximately $272.3 million as of the reporting period.

What Changed in RTW Investments' Natera Position

RTW Investments trimmed its position in Natera from 1.5 million shares to 1.25 million shares, a reduction of 250,000 shares. This change reflects a 16.67% decrease in its holdings. The shares are now valued at about $272.3 million.

Other Institutional Activity in Natera

JPMorgan Chase & Co. increased its holdings in Natera by 532,333 shares, ending up with 13,386,667 shares valued at roughly $2.50 billion. Similarly, Price T Rowe Associates added 1,312,887 shares, bringing its total to 12,184,876 shares worth about $2.44 billion. On the other hand, BlackRock, Inc. reduced its stake by 182,103 shares, holding 10,677,338 shares valued at $2.14 billion. Wellington Management Group also trimmed its position by 207,732 shares, now holding 4,768,593 shares with a value of approximately $953.7 million.

Natera Stock Snapshot

Shares of Natera, Inc. (NasdaqGS: NTRA) recently traded around $217.86. The company has a market cap of $30.37 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock has seen a 52-week low of $131.81 and a high of $256.36. It has a 50-day moving average of $206.64 and a 200-day moving average of $205.44. Natera's current ratio stands at 2.96, with a quick ratio of 2.70 and a debt-to-equity ratio of 13.53.

Recent Earnings

In its most recent earnings report, Natera posted revenue of $2.50 billion, reflecting a growth rate of 38.8%. However, the company reported a net margin of -9.05% and a return on equity of -15.02%. The next earnings release is scheduled for May 7, 2026.

Insider Buying and Selling at Natera, Inc.

Recent insider activity at Natera includes several transactions. On June 5, 2026, Marcus Gail Boxer sold 11,000 shares at an average price of $217.21 and purchased the same amount at $22.83. CEO Steven Leonard Chapman sold 41,124 shares at $221.03 on June 4, 2026, under a planned sale. Roelof Botha sold 78,000 shares at $220.31 on June 1, 2026, while Solomon Moshkevich sold 3,000 shares at $218.43 on the same day, also under a planned sale.

Analysts Set New Price Targets

Analysts have been active with new ratings and price targets for Natera. On June 12, 2026, RBC Capital reinstated coverage with a 'buy' rating and a $275 target. Goldman Sachs initiated coverage on June 5, 2026, with a 'hold' rating and a $245 target. Wolfe Research assumed coverage with a 'buy' rating and a $260 target on June 2, 2026. The consensus among 20 analysts is a 'buy' rating, with a mean price target of $260.05.

About Natera, Inc.

Natera, Inc., based in Austin, Texas, is a healthcare company specializing in diagnostics and research. It develops and sells various molecular testing services, including personalized cancer monitoring, hereditary cancer screening, and prenatal testing. With over 6,000 employees, Natera serves laboratories, medical centers, and pharmaceutical companies around the world.

Bottom Line

RTW Investments' decision to reduce its stake in Natera reflects a strategic adjustment in its portfolio. Investors often monitor such filings to gauge institutional confidence in a company's prospects. As a reminder, 13F filings are backward-looking and may not reflect current positions. Natera remains a significant player in the diagnostics industry, with ongoing analyst interest and a consensus 'buy' rating.